Literature DB >> 22037104

From whole blood to component therapy: the economic, supply/demand need for implementation of component therapy in sub-Saharan Africa.

O Erhabor1, T C Adias.   

Abstract

Blood may be transfused as whole blood or as one of its components. Because patients seldom require all of the components of whole blood, it makes sense to transfuse only that portion needed by the patient for a specific condition or disease. This treatment, known as "blood component therapy", allows several patients to benefit from one unit of donated whole blood. Blood components include red blood cells, plasma, platelets, and cryoprecipitate. A considerable literature has accumulated over the past decade indicating that leukocytes present in allogeneic cellular blood components, intended for transfusion, are associated with adverse effects to the recipient. These include the development of febrile transfusion reactions, graft-versus-host disease, alloimmunization to leukocyte antigens, and the immunomodulatory effects that might influence the prognosis of patients with a malignancy. Moreover, it has become evident that such leukocytes may be the vector of infectious agents such as cytomegalovirus (CMV), Human T-Lymphotrophic Virus 1/11 (HTLV-I/II), and Epstein Barr (EBV) as well as other viruses. Effective stewardship of blood ensuring that several patients potentially benefit from components derived from one unit of donated whole blood is important for economic, supply/demand reasons and to protect the national inventory at times of national blood shortage. Blood safety in developing countries can be improved by more appropriate use of blood components rather than whole blood transfusion and the provision of alternatives such as oral and intravenous iron, erythropoietin, saline and colloids. This will facilitate the optimal use of the limited blood supply. Political will and open-mindedness to innovative ways to improve supply, appropriateness, optimal use and safety of blood from all types of donors are essential to promote more evidence-based approaches to blood transfusion practice in sub-Saharan Africa.
Copyright © 2011. Published by Elsevier SAS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22037104     DOI: 10.1016/j.tracli.2011.06.001

Source DB:  PubMed          Journal:  Transfus Clin Biol        ISSN: 1246-7820            Impact factor:   1.406


  4 in total

Review 1.  Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak.

Authors:  Gary Wong; Gary P Kobinger
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

2.  Knowledge and practices of physicians on blood component therapy: a cross-sectional study from two tertiary hospitals in Nigeria.

Authors:  Esther Obi; Claudius Diette-Spiff; Hannah Omunakwe
Journal:  Afr Health Sci       Date:  2021-09       Impact factor: 0.927

3.  Diagnosis and treatment of bbstetrics disseminated intravascular coagulation in resource limited settings.

Authors:  Helen C Okoye; Theresa U Nwagha; Angela O Ugwu; Ifeanyi E Menuba; Augustine N Duru; Emmanuel O Ugwu; Feanyichukwu U Ezebialu; Stephen C Eze; Aloysuis O Ugwu
Journal:  Afr Health Sci       Date:  2022-03       Impact factor: 1.108

4.  Treatment with hyperimmune equine immunoglobulin or immunoglobulin fragments completely protects rodents from Ebola virus infection.

Authors:  Xuexing Zheng; Gary Wong; Yongkun Zhao; Hualei Wang; Shihua He; Yuhai Bi; Weijin Chen; Hongli Jin; Weiwei Gai; Di Chu; Zengguo Cao; Chong Wang; Quanshui Fan; Hang Chi; Yuwei Gao; Tiecheng Wang; Na Feng; Feihu Yan; Geng Huang; Ying Zheng; Nan Li; Yuetao Li; Jun Qian; Yong Zou; Gary Kobinger; George Fu Gao; Xiangguo Qiu; Songtao Yang; Xianzhu Xia
Journal:  Sci Rep       Date:  2016-04-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.